Today several pharmaceutical companies are set to meet with New York University assistant professor Jennifer Miller to find out how they scored on her soon-to-be released Good Pharma Scorecard—a comprehensive ranking that will show how effective they are at communicating results from clinical trials that lead up their drugs getting approved by the FDA. If the first iteration of this report, released last year, is any indication, some of the companies might not come off in such a flattering light.
Still, Miller believes grading Big Pharma on clinical trial transparency is essential to protecting public health.